# Parabilis Foundation Gives Free Oncology Pipeline

> Rare-disease foundation PBLS shares $1B+ oncology pipeline with Regeneron.
- Title: Parabilis Foundation Gives Free Oncology Pipeline | Shortify
- Summary: Rare-disease foundation PBLS shares $1B+ oncology pipeline with Regeneron. Parabilis Medicines leaves $1.1B oncology pipeline free for investors after IPO.
- Keywords: parabilis, regeneron, oncology, rare-disease, pipeline, ipo, money, business, Foundation, Gives, Free, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4955577-parabilis-1b-plus-rare-disease-foundation-leaves-the-big-oncology-pipeline-for-free
- Author: Stephen Ayers
- Published: 2026-10-20T17:14:51+00:00
- Read time: 1 min
- Topics: parabilis, regeneron, oncology, rare-disease, pipeline, ipo, money, business
## Parabilis Medicines Overview
Parabilis Medicines, Inc. (PBLS) IPO'd in June 2026 after surging to $42 in September.
## Investor Benefits
PBLS offers $1.1B cash, $125M Regeneron partnership, and cash runway into 2030.
## Lead Asset Efficacy
Zolucatetide shows robust early efficacy in desmoid tumors and craniopharyngioma.
## Market Position
PBLS trades at ~$24 with $3B market cap after 40% pullback from peak.
## Key takeaway

Parabilis Medicines leaves $1.1B oncology pipeline free for investors after IPO.